These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

395 related articles for article (PubMed ID: 21237145)

  • 1. Receptor-specific functional efficacies of alkyl imidazoles as dual histamine H3/H4 receptor ligands.
    Kottke T; Sander K; Weizel L; Schneider EH; Seifert R; Stark H
    Eur J Pharmacol; 2011 Mar; 654(3):200-8. PubMed ID: 21237145
    [TBL] [Abstract][Full Text] [Related]  

  • 2. N-Alkenyl and cycloalkyl carbamates as dual acting histamine H3 and H4 receptor ligands.
    Więcek M; Kottke T; Ligneau X; Schunack W; Seifert R; Stark H; Handzlik J; Kieć-Kononowicz K
    Bioorg Med Chem; 2011 May; 19(9):2850-8. PubMed ID: 21498080
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synthesis and in vitro pharmacology of a series of new chiral histamine H3-receptor ligands: 2-(R and S)-Amino-3-(1H-imidazol-4(5)-yl)propyl ether derivatives.
    Kovalainen JT; Christiaans JA; Kotisaari S; Laitinen JT; Männistö PT; Tuomisto L; Gynther J
    J Med Chem; 1999 Apr; 42(7):1193-202. PubMed ID: 10197963
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 4-(omega-(alkyloxy)alkyl)-1H-imidazole derivatives as histamine H(3) receptor antagonists/agonists.
    Meier G; Krause M; Hüls A; Ligneau X; Pertz HH; Arrang JM; Ganellin CR; Schwartz JC; Schunack W; Stark H
    J Med Chem; 2004 May; 47(10):2678-87. PubMed ID: 15115409
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cyclopropane-based stereochemical diversity-oriented conformational restriction strategy: histamine H3 and/or H4 receptor ligands with the 2,3-methanobutane backbone.
    Watanabe M; Kobayashi T; Hirokawa T; Yoshida A; Ito Y; Yamada S; Orimoto N; Yamasaki Y; Arisawa M; Shuto S
    Org Biomol Chem; 2012 Jan; 10(4):736-45. PubMed ID: 22120611
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Histamine H3 and H4 receptor affinity of branched 3-(1H-imidazol-4-yl)propyl N-alkylcarbamates.
    Łazewska D; Wiecek M; Ligneau X; Kottke T; Weizel L; Seifert R; Schunack W; Stark H; Kieć-Kononowicz K
    Bioorg Med Chem Lett; 2009 Dec; 19(23):6682-5. PubMed ID: 19846299
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Triazole ligands reveal distinct molecular features that induce histamine H4 receptor affinity and subtly govern H4/H3 subtype selectivity.
    Wijtmans M; de Graaf C; de Kloe G; Istyastono EP; Smit J; Lim H; Boonnak R; Nijmeijer S; Smits RA; Jongejan A; Zuiderveld O; de Esch IJ; Leurs R
    J Med Chem; 2011 Mar; 54(6):1693-703. PubMed ID: 21348462
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A selective human H(4)-receptor agonist: (-)-2-cyano-1-methyl-3-[(2R,5R)-5- [1H-imidazol-4(5)-yl]tetrahydrofuran-2-y] methylguanidine.
    Hashimoto T; Harusawa S; Araki L; Zuiderveld OP; Smit MJ; Imazu T; Takashima S; Yamamoto Y; Sakamoto Y; Kurihara T; Leurs R; Bakker RA; Yamatodani A
    J Med Chem; 2003 Jul; 46(14):3162-5. PubMed ID: 12825954
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Structural requirements for inverse agonism and neutral antagonism of indole-, benzimidazole-, and thienopyrrole-derived histamine H4 receptor ligands.
    Schneider EH; Strasser A; Thurmond RL; Seifert R
    J Pharmacol Exp Ther; 2010 Aug; 334(2):513-21. PubMed ID: 20484153
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tritium-labeled N(1)-[3-(1H-imidazol-4-yl)propyl]-N(2)-propionylguanidine ([(3)H]UR-PI294), a high-affinity histamine H(3) and H(4) receptor radioligand.
    Igel P; Schnell D; Bernhardt G; Seifert R; Buschauer A
    ChemMedChem; 2009 Feb; 4(2):225-31. PubMed ID: 19101971
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Stereochemical diversity-oriented conformational restriction strategy. Development of potent histamine H3 and/or H4 receptor antagonists with an imidazolylcyclopropane structure.
    Watanabe M; Kazuta Y; Hayashi H; Yamada S; Matsuda A; Shuto S
    J Med Chem; 2006 Sep; 49(18):5587-96. PubMed ID: 16942032
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Compared pharmacology of human histamine H3 and H4 receptors: structure-activity relationships of histamine derivatives.
    Gbahou F; Vincent L; Humbert-Claude M; Tardivel-Lacombe J; Chabret C; Arrang JM
    Br J Pharmacol; 2006 Apr; 147(7):744-54. PubMed ID: 16432504
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification and pharmacological characterization of a series of new 1H-4-substituted-imidazoyl histamine H3 receptor ligands.
    Yates SL; Phillips JG; Gregory R; Pawlowski GP; Fadnis L; Khan MA; Ali SM; Tedford CE
    J Pharmacol Exp Ther; 1999 May; 289(2):1151-9. PubMed ID: 10215699
    [TBL] [Abstract][Full Text] [Related]  

  • 14. No evidence for functional selectivity of proxyfan at the human histamine H3 receptor coupled to defined Gi/Go protein heterotrimers.
    Schnell D; Burleigh K; Trick J; Seifert R
    J Pharmacol Exp Ther; 2010 Mar; 332(3):996-1005. PubMed ID: 19959746
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clobenpropit analogs as dual activity ligands for the histamine H3 and H4 receptors: synthesis, pharmacological evaluation, and cross-target QSAR studies.
    Lim HD; Istyastono EP; van de Stolpe A; Romeo G; Gobbi S; Schepers M; Lahaye R; Menge WM; Zuiderveld OP; Jongejan A; Smits RA; Bakker RA; Haaksma EE; Leurs R; de Esch IJ
    Bioorg Med Chem; 2009 Jun; 17(11):3987-94. PubMed ID: 19414267
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular determinants of ligand binding modes in the histamine H(4) receptor: linking ligand-based three-dimensional quantitative structure-activity relationship (3D-QSAR) models to in silico guided receptor mutagenesis studies.
    Istyastono EP; Nijmeijer S; Lim HD; van de Stolpe A; Roumen L; Kooistra AJ; Vischer HF; de Esch IJ; Leurs R; de Graaf C
    J Med Chem; 2011 Dec; 54(23):8136-47. PubMed ID: 22003888
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synthesis and functional characterization of imbutamine analogs as histamine H3 and H4 receptor ligands.
    Geyer R; Kaske M; Baumeister P; Buschauer A
    Arch Pharm (Weinheim); 2014 Feb; 347(2):77-88. PubMed ID: 24493592
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cyclopropane-based conformational restriction of histamine. (1S,2S)-2-(2-aminoethyl)-1-(1H-imidazol-4-yl)cyclopropane, a highly selective agonist for the histamine H3 receptor, having a cis-cyclopropane structure.
    Kazuta Y; Hirano K; Natsume K; Yamada S; Kimura R; Matsumoto S; Furuichi K; Matsuda A; Shuto S
    J Med Chem; 2003 May; 46(10):1980-8. PubMed ID: 12723960
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Selective histamine H₃ and H₄ receptor agonists exert opposite effects against the gastric lesions induced by HCl in the rat stomach.
    Coruzzi G; Adami M; Pozzoli C; de Esch IJ; Smits R; Leurs R
    Eur J Pharmacol; 2011 Nov; 669(1-3):121-7. PubMed ID: 21839070
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Interactions of histamine H1-receptor agonists and antagonists with the human histamine H4-receptor.
    Deml KF; Beermann S; Neumann D; Strasser A; Seifert R
    Mol Pharmacol; 2009 Nov; 76(5):1019-30. PubMed ID: 19720730
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.